Abstract P254: Willingness to Restart Statins: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Introduction: Many patients who discontinue statins due to side effects can restart treatment without the return of side effects. However, statin rechallenge is often met with resistance. Statins are associated with a larger absolute cardiovascular disease (CVD) risk reduction among high risk individuals, but it is unclear whether individuals with higher CVD risk are more willing to be rechallenged.
Methods: Between 2014 and 2016, 12,604 participants in theREasons for Geographic and Racial Differences in Stroke study completed a study examination and a questionnaire about their experiences with statins. Of 6,947 participants who reported ever having taken a statin, this analysis included the 688 (9.9%) who reported having discontinued treatment due to side effects and who were not currently taking a statin. We asked participants whether they would be willing to restart a statin, and among those who answered no, we asked whether they were willing to restart at a lower dose or less frequently. Data from the study examination were used to define CVD risk factors and 10-year predicted CVD risk was calculated using the Pooled Cohort risk equations.
Results: Participant mean age was 62.4 years, 29.6% were African American, and 66.4% were women. Overall, 26.0% (n=179) of participants were willing to be rechallenged with a statin (Table). After adjustment for sociodemographic characteristics, older age, cigarette smoking, hypertension, diabetes, or history of CVD were not associated with an increased willingness to be rechallenged with a statin (Table). Higher 10-year predicted CVD risk was also not associated with willingness to be rechallenged.
Conclusions: Over a quarter of participants who discontinued statin treatment due to side effects were willing to be rechallenged. The presence of CVD risk factors and higher predicted CVD risk were not associated with increased willingness to be rechallenged with a statin.
Author Disclosures: G.S. Tajeu: None. L.D. Colantonio: None. R.M. Tanner: None. K.L. Monda: A. Employment; Significant; Amgen, Inc. R. Dent: A. Employment; Significant; Amgen, Inc., Esperion Therapeutics. F. Ownership Interest; Modest; Amgen, Inc.. F. Ownership Interest; Significant; Esperion Therapeutics. M.E. Farkouh: C. Other Research Support; Significant; Amgen, Inc. B. Taylor: A. Employment; Significant; Amgen, Inc. R.S. Rosenson: B. Research Grant; Significant; Amgen, Inc, Astra Zeneca, Catabasis, Medicines Company. E. Honoraria; Significant; Kowa. G. Consultant/Advisory Board; Modest; Akcea, Amgen, Astra Zeneca, C5, Eli Lilly, Regenron, Sanofi. H. Other; Significant; Royalties. M.M. Safford: B. Research Grant; Significant; Amgen, Inc. G. Consultant/Advisory Board; Modest; Amgen, Inc. P. Muntner: B. Research Grant; Significant; Amgen, Inc.
- © 2017 by American Heart Association, Inc.